An accomplished leader in cancer biology and drug discovery with a proven track record of advancing five development candidates to the clinic, including contributing to the development of one FDA-approved drug. Led teams in delivering drug candidates and preclinical data for biomarker-driven combination trials. Author of 38 publications and inventor on two patents. Known for strong verbal and written communication skills, team-building, and problem-solving abilities, with extensive experience collaborating with cross-functional teams to successfully lead projects from discovery through to the clinic.Led multi-disciplinary team to develop complex multi-phenotypic ultra-high throughput screening assays (DNA Encoded Library of small molecule screen for multiple classes of targets, kinases, PPI, GTPases, RNABPs, RTKs, methyltransferase, and Transcription factors), IF, cell painting, co-culture antibody functional screen and biologicsTeam leader in the discovery of the innovative MNK1/2 inhibitor (eFT508) concept in immuno-oncology and CAR T cell program, which set a new milestone at eFFECTOR Therapeutics for developing the combination trials of eFT508 with ICI with partnersAs a group leader, fostering a collaborative and productive matrix work environment Managing multiple CROs for the in-vivo pharmacology, murine TGI in CDX, PDX, syngeneic, and GEMM models, PK/PD, MTD and DRF studiesLed the discovery and development of novel translational PD biomarkers assay for Phase I/II clinical trials. Design and execute the PK/PD analysis and in vivo response evaluation of drug candidates for targeted single-agent or combination therapiesDevelop the preclinical translational data to differentiate PHASE I/II assets from competitors, extend the life cycle of clinical assets for bucket clinical trialsWrote major sections (non-clinical pharmacology) of IND (tomivosertib), IB, DSUR, IND (elzoventinib, TPX-0131), ODD (elzoventinib and TPX-0131), IMPD (elzoventinib), and NDA(repotrectinib)Active partner with the Business Development team for SWOT analysis, competitive intelligence, and due diligence of a wide range (small molecules, degraders, and biotherapeutics) of early to late targets for licensing Inviting KOLs and working with SAB team members, key stakeholders, and academic experts to initiate and oversee investigator-sponsored studies to advance the pipeline and translational projectsCore team member responsible for managing the portfolio strategies, preparing the data package, and presenting to the Executive Leadership Team and external partners
Listed skills include Cell Culture, Cell Biology, Cell, Molecular Biology, and 59 others.